On the variation of glycosylation in human plasma derived antithrombin

被引:29
作者
Demelbauer, UM
Plematl, A
Josic, D
Allmaier, G
Rizzi, A
机构
[1] Univ Vienna, Inst Analyt Chem, A-1090 Vienna, Austria
[2] Octapharma Pharmazeut Prod Gesell, A-1100 Vienna, Austria
[3] Vienna Univ Technol, Inst Chem Technol & Analyt, A-1060 Vienna, Austria
[4] Brown Univ, Sch Med, COBRE Canc Reg Program, Providence, RI 02903 USA
关键词
antithrombin; glycoform analysis; glycoproteins; lectin-affinity chromatography; tandem mass spectrometry;
D O I
10.1016/j.chroma.2005.01.057
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The paper presents data on the primary structure of the glycan variants present in human antithrombin (AT) isoforms obtained from a plasma pool. The analysis is conducted on the level of glycopeptides gained by tryptic digestion. The glycopeptides were pre-separated by lectin-affinity chromatography and analyzed by means of electrospray ionization-tandem mass spectrometry involving collision-induced dissociation. Variations of the canonical biantennary complex-type structure were present with relative abundances of about 1-5% and most of them were found site-specifically. Core fucosylation was observed at one single glycopeptide only (peptide containing N-155), triantennary glycan structures with two glycopeptides (containing N-155 and N-135). Deficiency of one terminal sialic acid was observed as not site-specific. Fucosylation was not yet reported to be present in human AT from plasma, opposite to recombinant human AT from baby hamster kidney cells, which was reported as fully core fucosylated. In total, the variability in the carbohydrate structure of plasma derived AT appears as being quite limited. This might be of significance in the context of the reported correlation between glycosylation and physiological activity. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:15 / 21
页数:7
相关论文
共 22 条
[1]   PHYSIOLOGICAL VARIANT OF ANTITHROMBIN-III LACKS CARBOHYDRATE SIDE-CHAIN AT ASN-135 [J].
BRENNAN, SO ;
GEORGE, PM ;
JORDAN, RE .
FEBS LETTERS, 1987, 219 (02) :431-436
[2]   High-performance capillary electrophoresis for in-process control in the production of antithrombin III and human clotting factor IX [J].
Buchacher, A ;
Schulz, P ;
Choromanski, J ;
Schwinn, H ;
Josic, D .
JOURNAL OF CHROMATOGRAPHY A, 1998, 802 (02) :355-366
[3]  
CONARD J, 1983, HAEMOSTASIS, V13, P363
[4]   ANALYSIS OF ANTITHROMBIN-III MICROHETEROGENEITY BY ISOELECTRIC-FOCUSING IN POLYACRYLAMIDE GELS AND IMMUNOBLOTTING [J].
DALY, M ;
HALLINAN, F .
THROMBOSIS RESEARCH, 1985, 40 (02) :207-214
[5]   Determination of glycopeptide structures by multistage mass spectrometry with low-energy collision-induced dissociation: comparison of electrospray ionization quadrupole ion trap and matrix-assisted laser desorption/ionization quadrupole ion trap reflectron time-of-flight approaches [J].
Demelbauer, UM ;
Zehl, M ;
Plematl, A ;
Allmaier, G ;
Rizzi, A .
RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2004, 18 (14) :1575-1582
[6]   Characterization of glyco isoforms in plasma-derived human antithrombin by on-line capillary zone electrophoresis-electrospray ionization-quadrupole ion trap-mass spectrometry of the intact glycoproteins [J].
Demelbauer, UM ;
Plematl, A ;
Kremser, L ;
Allmaier, M ;
Josic, D ;
Rizzi, A .
ELECTROPHORESIS, 2004, 25 (13) :2026-2032
[7]   Transgenically produced human antithrombin: Structural and functional comparison to human plasma-derived antithrombin [J].
Edmunds, T ;
Van Patten, SM ;
Pollock, J ;
Hanson, E ;
Bernasconi, R ;
Higgins, E ;
Manavalan, P ;
Ziomek, C ;
Meade, H ;
McPherson, JM ;
Cole, ES .
BLOOD, 1998, 91 (12) :4561-4571
[8]  
Fitton HL, 1997, BIOL CHEM, V378, P1059
[9]  
FRANZEN LE, 1980, J BIOL CHEM, V255, P5090
[10]   Thrombin inhibition by antithrombin III on the subendothelium is explained by the isoform AT beta [J].
Frebelius, S ;
Isaksson, S ;
Swedenborg, J .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1996, 16 (10) :1292-1297